Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer.
OBJECTIVE
This review describes the early clinical development of uracil-ftorafur (UFT), an oral fluoropyrimidine, designed in 1978 by adding uracil to ftorafur. The review focuses on the treatment of colorectal cancer and summarizes the Japanese experience and the phase I and II trials performed in the United States and Europe.


RESULTS
Clinical trials of UFT published in the Western world have included 581 patients with colorectal cancer. UFT has been administered in these trials as a single agent or biomodulated by leucovorin (LV). UFT was administered daily in split doses for periods that ranged from 14 to 28 days. The activity of oral UFT in large-bowel cancer when administered with oral LV (approximately 50 mg/dose) has resulted in objective response rates of approximately 40%. Response rates of approximately 25% (range, 17% to 39%) were reported when UFT was administered as a single agent or with lower doses of LV. The highest dose-intensities of UFT are achieved with 28-day schedules of administration. The maximum-tolerated dose (MTD) of UFT with this schedule, when administered concomitantly with oral LV 150 mg daily, is 300 mg/m2 daily. The dose-limiting toxicity (DLT) of UFT has generally been diarrhea. Other commonly described toxicities include nausea and vomiting, fatigue, and stomatitis. Myelosuppression occurs infrequently. Typically, hand-foot syndrome and neurologic toxicity are lacking.


CONCLUSIONS
UFT is a fluoropyrimidine active in colorectal cancer. The oral route of administration and improved safety profile represent important advantages over both conventional and infusional fluorouracil (5-FU) regimens.
Sulkes
A
A
Department of Clinical Oncology, Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Wallingford, CT, USA. asolkes@ccsg.tau.ac.il
Benner
S E
SE
Canetta
R M
RM
D000284:Administration, Oral; D000931:Antidotes / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000601:surgery; D004334:Drug Administration Schedule; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D005641:Tegafur / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use*
D000931:Antidotes; D000964:Antimetabolites, Antineoplastic; D005641:Tegafur; D002955:Leucovorin